

Custom Contract Manufacturing Since 1980. Enriching the World Through the Best of Nutrition.



## Natural Alternatives International, Inc.

**Investor Presentation** 

February 2022

# **Forward Looking Statements**

This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934.

These statements reflect Natural Alternatives International, Inc.'s (the Company's) current views about future events and financial performance based on certain assumptions. They include the Company's intentions, projections, expectations and beliefs about the Company's future financial and operating results, including management's goals for future operations, industry performance, characteristics and opportunities, effectiveness of distribution channels and customers.

For this purpose, any statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. These statements speak only as of the date of this presentation and are subject to certain risks and uncertainties that could cause actual results to differ materially. This presentation is qualified by the risks and other information set forth in the Company's Form 10-K filed with the SEC.

These forward-looking statements are made only as of the date hereof, and Natural Alternatives undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.



# Regulation G

In addition, in order to assist you with period-over-period comparisons on a consistent and comparable basis, our presentation includes certain non-US GAAP information. This information excludes certain non-cash expenses, certain cash income and expense items related to our foreign currency hedging program and taxes, as well as certain non-recurring income and expense items related to the gain on sale of our Company's former headquarters, and the one-time write-off of accounts receivable and inventory related to a former customer.

This non-US GAAP information may include non-US GAAP financial measures within the meaning of Regulation G. These non-US GAAP measures should not be considered as a substitute for any measure derived in accordance with US GAAP. The non-US GAAP information may also be inconsistent with the manner in which similar measures are derived or used by other companies. Management uses such non-US GAAP information for financial and operational decision-making purposes and as a means to evaluate period-over-period comparisons and in forecasting the Company's business going forward.

Management believes that the presentation of such non-US GAAP information, when considered in conjunction with the most directly comparable US GAAP information, provides additional useful comparative information for investors in their assessment of the underlying performance of the Company's business with regard to these items. The Company has provided reconciliations of such non-US GAAP financial measures to the most directly comparable financial measures prepared in accordance with US GAAP. The reconciliations are included in this presentation.

# **Company Snapshot**

NAII is the only pure-play public company that offers global formulation and manufacturing of customized nutritional supplements along with marketing branded and patented products



#### **Contract Manufacturing**

We provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements and health care products to consumers



#### **Patent & Trademark Licensing**

In-house brand leveraging our proprietary ingredients CarnoSyn® and SR CarnoSyn® targeting sports nutrition, wellness, and healthy aging markets



Headquarters: Carlsbad, CA

Founded in 1980

Nasdaq: NAII

Total Revenue (TTM)\*: \$167M

**Market Capitalization:** \$82M

(as of 2/3/2022)

# **Company Strengths**

### Multi-Continent Contract Manufacturing Facilities

- Custom product formulation
- State-of-the-art manufacturing facilities
- Broad material acquisition & analysis
- Certified in-house laboratory capabilities
- Multiple packaging configuration capabilities





### In-House Brand Leveraging Of Our Proprietary Ingredients

- CarnoSyn® and SR CarnoSyn® targeting sports nutrition, wellness, and healthy aging markets
- Direct-to-consumer launched June 2020

# **Company Strengths**

## Growth Drivers From Organic Initiatives And Complementary Acquisitions

- Expand existing customer products, base and channels
- Expand in-house brands
- Complementary acquisitions





## Solid Cash Flows And Strong Balance Sheet To Support Growth Objectives

- TTM net sales of \$166.8 million
- Working Capital of \$54.1 million at 12/31/21
- \$20M available line of credit at 12/31/21

# **Executive Management Team**



## Mark A. LeDoux CEO and Chairman of the Board of Directors

Mr. LeDoux founded Natural Alternatives International (NAI) in 1980. With over 45 years of experience since joining the nutritional supplements industry in 1975, Mr. LeDoux is considered a highly regarded leader and spokesperson for our industry – making him one of the longest serving active executives in the nutritional supplements industry. As Chairman of the Board of Directors of the prestigious Natural Products Association (NPA) based in Washington DC, where he has been a member since 1980, Mr. LeDoux represents NAI's ongoing commitment to industry and government affairs, adherence to a strong code of ethics, and continuing support in the legislative, regulatory and public affairs arenas.

He was former Chairman and Board member of the esteemed Council for Responsible Nutrition (CRN) and Founding Chairman of CRN International. LeDoux also serves on the Nutrition Industry Associationwest (NIA) Board and is a recognized participant of the Codex Alimentarius Commission, the United Nations' food and dietary supplement standard-setting body under the joint supervision of its Food and Agriculture Organization and World Health Organization.

In addition, LeDoux currently serves as Chairman of the Board of Selectmen in his hometown of Hollis, New Hampshire. He is President of the Marie A. LeDoux Charitable Foundation and a current member of the Young Presidents Organization Graduates. A graduate of the Thomas Jefferson School of Law, Mr. LeDoux received his bachelor's degree from the University of Oklahoma, where he graduated with honors. He is also a graduate of Stanford University's Program for Small Business Executives.

# **Executive Management Team**



# Kenneth E. Wolf President and Chief Operating Officer

Mr. Wolf joined NAI in February 2008 as Chief Financial Officer, was promoted to Chief Operating Officer in June 2010 and has served as NAI's President since October 2015. Mr. Wolf is responsible for design and implementation of NAI's long-term strategic plans and oversight of all areas within the company. He possesses over 26 years of senior financial management experience in both publicly traded and privately held companies, with the prior 21 years associated with consumer products manufacturing companies. Mr. Wolf received his Certified Public Accountant license from the State of California and a Bachelor of Science in Business Administration – Accounting from California State University in Fresno, California.



# Michael E. Fortin Chief Financial Officer

Mr. Fortin joined NAI in April 2008 as Director of Accounting and SEC Reporting and earned his appointment to Chief Financial Officer in October 2015. With over 20 years of accounting and finance experience working in Big 4 public accounting and private industry, Mr. Fortin is a steadfast, strategic leader responsible for driving financial and business results. Mr. Fortin received his Certified Public Accountant license from the State of California and a Bachelor of Science in Business Administration-Accounting from San Diego State University, California.

# Overview - Capabilities

#### **Global Production**

- Up to 20 million capsules and 14 million tablets daily capacity
- Up to 500,000 bottles finished product daily capacity
- Highly sophisticated in-house laboratories
- Warehousing 7,200+ pallet capacity

### Regulatory

- Full Label Panel Testing and Quality Assurance
- DSHEA and FDA compliant labeling
- International product registration support

### **Intellectual Property**

- 11 US Patents
- 20 total corresponding patents registered throughout North America, Europe, Asia
- 14 US trademark registrations
- 35 foreign trademark registrations, covering 41 countries

### **Sales & Marketing**

- Experienced global sales and marketing team
- Strong brand recognition in sports nutrition
- World class customer service



## **Overview – Contract Manufacturing**

#### **Product Formulation**

- Custom formulations
- In-house science teams
- Clinical study design and support
- In-house product stability testing capabilities

### **Material Acquisition and Analysis**

- · Global raw material sourcing expertise
- Transparency and tracking of material sources
- Extensive vendor certification program

#### **Facilities**

- Vista, CA USA (162,000 SF manufacturing)
- Carlsbad, CA USA (21,000 SF office space)
- Carlsbad, CA USA (54,000 SF manufacturing)
- Manno, Switzerland (127,000 SF manufacturing)

#### **Forms**

Capsules



Tablets



Chewables



Powders







## **Overview – Patent & Trademark Licensing**

In-house brand expansion leveraging our proprietary ingredients: CarnoSyn® and SR CarnoSyn® beta-alanine.







Please visit websites by clicking on logo.

#### **Sports Nutrition**

- Enhance athletic performance
- Build muscle and reach peak sustainable performance
- New sustained release form of CarnoSyn® remains in the body longer
- · New Dietary Ingredient (NDI) Status with the FDA
- Self-Affirmed GRAS Status
- The Natural Products Association 2019 Novel Ingredient and Science Award Recipient
- 2019 NutraIngredients Sports Nutrition Ingredient of the Year

#### **Health & Wellness**

- · Improves everyday muscle capacity and health
- "Wellness" and "Healthy Aging" products
- Specifically formulated for the health care practitioner market
- Self-Affirmed GRAS Status

#### **Direct-to-Consumer**

- Immunity boost, mental clarity, total body wellness
- Launched June 2020
- Sold exclusively on Amazon
- Provides platform for additional DTC products



## **Worldwide Operations and Market Reach**

NAI's global footprint and scope facilitates greater opportunities and more dynamic client engagement



## **NAI US Facilities Tour**



## **Accreditations**

Industry leading accreditations and certification demonstrate our commitment to quality and are a strong barrier to entry

### **Domestic (NAI)**

Good Manufacturing Practices (cGMPs) (21 CFR 111) compliant – FDA Inspected; Zero 483 observations

Therapeutic Goods Administration (TGA) GMP Compliance certified

Health Canada (NNHPD) GMP Compliance – Foreign Site Reference Number issued

NSF International – GMP certified (21 CFR 111 & 21 CFR 117)

NSF International – GMP for Sport certified

Certified Organic (Natural Food Certifiers)

Supplement Safety & Compliance Initiative (SSCI) certification

### **International (NAIE)**

SwissMedic GMP certified – site registered and licensed

Laboratorio cantonale - inspected and certified under Official Food Law Enforcement Authority

Informed Choice/Informed Sport (LGC) certified

Institut Fresenius (SGS) GMP Certified

SGS Hazard Analysis and Critical Control Point (HACCP) Codex Alimentarius Certified























# **Industry Trends**

## We will benefit from growing consumer interest in health and wellness



of consumers say supplements are part of a healthy lifestyle <sup>1</sup>



of consumers take supplements daily <sup>2</sup>



76% of baby boomers take supplements <sup>2</sup>

### Growing vitamin, mineral, & supplement ("VMS") industries:

- USA Dietary supplement market is estimated at US \$55 billion and projected to grow at a 4.6% CAGR through 2023<sup>3</sup>
- Global Dietary supplement market is estimated at US \$150 billion and projected to grow at a 4.6% CAGR through 2023<sup>3</sup>




## **COVID-19 Spikes USA Supplement Growth**


COVID accelerated the supplement growth trend. Supplements projected to be \$1.4B larger in 2023 than pre-COVID est.



# **US Supplement Market Forecast**


A new level of demand has been established; Supplement industry on track to pass \$55B in 2020 and grow to \$60B+ by 2023






# **Global Supplement Market Forecast**

Global trend is matching US trend Global market spike of 9.5% growth to \$150B in 2020.










## **Financial Performance and Growth Objectives**


## **Historical Revenue and EBITDA**

Sales in FY21 increased primarily due to higher sales from a majority of our distribution channels worldwide, including higher sales of immune and wellness products that appears to be driven by consumers taking a more active role in their health and wellness as a result of the COVID-19 pandemic. We also added new products from existing customers and new products from new customer acquisitions.





# **Historical Sales By Channel**





# **Objectives & Growth Drivers**

#### Full Year Fiscal 2022 Outlook:

- ✓ Net Sales flat to slightly up
- ✓ Operating Income of 8-11% of Net Sales

### Outlook for the 2nd Half of Fiscal 2022:

- √ 10-13% increase in Net Sales
- ✓ Operating Income of 8-11% of Net Sales

## Fiscal 2023 and Beyond Targeted Growth Objectives:

- ✓ Achieve \$250 million revenue run-rate in the next 1-2 years with double digit Adjusted EBITDA margins
- ✓ Target sales growth rate of 5-10% per year
- ✓ Pursue complimentary accretive acquisitions generating \$10-\$50 million in sales over the next 3 years



# **Acquisition Strategy**



#### Channels

Health Care Practitioner
Multi-Level Marketer
Direct-to-Consumer
Specialty Retail
Drug Store
Mass



### Markets

Vitamins, Minerals, Supplements Personal Care Over-the-Counter



### **Verticals**

Wellness Brands
High Value Ingredient Suppliers
Contract Manufacturers
Value-Add Distributors



#### **Forms**

Capsules/Tablets, Powders
Liquids, Lotions, Creams
Chewable Wafers, Gummy/Soft-Chew
Effervescent, Strips, Patches
Probiotics

## **Investment Thesis**

- As of February 9, 2022, capacity utilization of ~60%
  - New high-capacity blender came online January 2022 in our Vista, CA facility increasing our overall product blending capacity in the USA by approximately 30%
  - Acquisition of new Manufacturing and Warehouse Facility in August 2021:
    - To be retrofitted to become a dedicated high volume powder blending and packaging facility by the fall of calendar 2022
    - Facility expected to provide substantially more warehouse, blending, and powder packaging capacity
    - Positioned to take advantage of current opportunities as well as new potential opportunities in the growing market of whole-food-based meal replacement powders as well as other powder product types
- As utilization increases, fixed costs remain relatively flat and profit margins improve
- Solid financial condition and ability to generate strong cash flow will allow us to increase capacity and or seek acquisition opportunities
- As of December 31, 2021 trading at under 4.8x EV/Adjusted EBITDA



## **Investor Information**

Stock Symbol: NASDAQ: NAII

Company website: <a href="http://www.nai-online.com">http://www.nai-online.com</a>

## **Company Headquarters:**

1535 Faraday Avenue Carlsbad, CA 92008

#### **Investor Relations Contacts**

Michael Fortin Chief Financial Officer 760-736-7700 investor@nai-online.com











# **Appendix**

**Investor Relations Info** 

# **Historical Segment Performance**

		Fiscal Year ended June 30,					Trailing 12 Months*	
	2019		2020		2021		(Una	udited)
Revenue								
Private Label Contract Manufacturing	\$	121,598	\$	106,291	\$	164,310	\$	149,208
Patent & Trademark Licensing		16,692		12,585		14,210		17,570
Total Revenue	\$	138,290	\$	118,876	\$	178,520	\$	166,778
Income (Loss) from Operations								
Private Label Contract Manufacturing	\$	11,232	\$	4,030	\$	17,744	\$	13,938
Patent & Trademark Licensing		2,892		2,508		4,442		7,636
Income from operations of reportable segments		14,124		6,538		22,186		21,574
Corporate expense not allocated to segments		(8,163)		(8,047)		(8,514)		(8,750)
Income (Loss) from Operations	\$	5,961	\$	(1,509)	\$	13,672	\$	12,824
Revenue as a %								
Private Label Contract Manufacturing		87.9%		89.4%		92.0%		89.5%
Patent & Trademark Licensing		12.1%		10.6%		8.0%		10.5%
Operating Margins								
Private Label Contract Manufacturing		9.2%		3.8%		10.8%		9.3%
Patent & Trademark Licensing		17.3%		19.9%		31.3%		43.5%
Income from Operations of reportable segments		10.2%		5.5%		12.4%	454	129%
Income from Operations		4.3%		-1.3%		7.7%		7.7%



## **Condensed Consolidated Statements of Income**

(In thousands, except per share data)
(Unaudited)

	Thre	ee Months E	nded		Six N	Months Ended	ł	
		December 3	1,		De	ecember 31,		
	2021		2020		2021		2020	
NET SALES	37,727	100.0%	48,083	100.0%	76,067	100.0%	87,809	100.0%
Cost of goods sold	31,181	82.6%	38,409	79.9%	61,240	82.1%	72,130	82.1%
Gross profit	6,546	17.4%	9,674	20.1%	14,827	17.9%	15,679	17.9%
Selling, general & administrative expenses	4,145	11.0%	4,282	8.9%	8,198	9.3%	8,202	9.3%
INCOME FROM OPERATIONS	2,401	6.4%	5,392	11.2%	6,629	8.5%	7,477	8.5%
Other (loss) income, net	(9)	-1.7%	(806)	-1.7%	(35)	-1.3%	(1,127)	-1.3%
INCOME BEFORE TAXES	2,392	9.5%	4,586	9.5%	6,594	7.2%	6,350	7.2%
Income tax expense	545		954		1,491		460	
NET INCOME	\$ 1,847		\$ 3,632		\$ 5,103		\$ 5,890	
NET INCOME PER COMMON SHARE:	ćo 20		¢0.50		40.02		60.00	
Basic:	\$0.30		\$0.58		\$0.82		\$0.93	
Diluted:	\$0.30		\$0.57		\$0.81		\$0.92	
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:								
Basic	6,212		6,270		6,250		6,344	
Diluted	6,256		6,405		6,304		6,438	



## **Condensed Consolidated Balance Sheets**

(In	thousands)	
	December 31,	June 30,
	2021	2021
	(Unaudited)	
ASSETS		
Cash and cash equivalents	\$19,352	\$32,133
Accounts receivable, net	15,065	17,946
Inventories, net	31,828	27,006
Other current assets	<u>4,316</u>	3,263
Total current assets	70,531	80,348
Property and equipment, net	39,741	22,271
Operating lease right-of-use assets	14,542	15,877
Other noncurrent assets, net	<u>2,514</u>	<u>1,785</u>
Total Assets	<u>\$127,358</u>	<u>\$120,281</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Accounts payable and accrued liabilities	17,874	23,717
Mortgage	9,932	_
Long-term liability - operating leases	<u>15,151</u>	<u>16,481</u>
Total Liabilities	<u>42,957</u>	<u>40,198</u>
Stockholders' Equity	84,401	80,083
Total Liabilities and Stockholders' Equity	<u>\$127,358</u>	<u>\$120,281</u>



## Adjusted EBITDA Reconciliation (Non-US GAAP)

Natural Alternatives International, Inc. Adjusted EBITDA – Non – US GAAP Reconciliation							
(In Thousands)							Trailing 12
(Unaudited)	FY16	FY17	FY18	FY19	FY20	FY21	Months*
Net Income (Loss)	\$9,546	\$7,235	\$5,051	\$6,541	(\$1,645)	\$10,768	\$9,981
Interest Income	(131)	(459)	(1,085)	(1,868)	(177)	(1)	1
Interest Expense	(2)	3	9	29	66	118	49
Taxes	4,026	2,876	5,562	1,412	(93)	1,358	2,388
Depreciation & Amortization	1,772	2,384	2,908	3,465	3,959	4,338	4,346
Traditional EBITDA	\$15,211	\$12,039	\$12,445	\$9,579	\$2,110	\$16,581	\$16,764
Non-cash Compensation	724	1,032	1,334	1,672	1,712	1,430	1,199
Non-cash Sales Discount	_	_	898	82	Q -	_	/2-
Forward Pts in Revenue	_	_	<del>-</del>	<u> </u>	(863)	(518)	(410)
Acquisition Costs	_	<u>-</u>	117	512	30		_
Foreign Exchange (Gain) Loss	425	28	(18)	(148)	320	1,408	385
One Time Gain on Building	(1,621)	<u> </u>	_	_		<u> </u>	_
One Time Kaged Muscle Adjustment**				<u> </u>	4,288	(696)	(112)
Adjusted EBITDA	\$14,739	\$13,099	\$14,776	\$11,697	\$7,597	\$18,205	\$17,826





## Custom Contract Manufacturing Since 1980. Enriching the World Through the Best of Nutrition.



## **Thank You**

www.nai-online.com